Reduction in Acute Gastroenteritis Hospitalizations among US Children After Introduction of Rotavirus Vaccine: Analysis of Hospital Discharge Data from 18 US States

Background. In 2006, RotaTeq (RV5) was recommended for routine vaccination of United States (US) infants. We compared hospitalization rates for acute gastroenteritis among US children aged <5 years during pre-RV5 rotavirus seasons from 2000 through 2006 with those during the post-RV5 2007 and 200...

Full description

Saved in:
Bibliographic Details
Published inThe Journal of infectious diseases Vol. 201; no. 11; pp. 1617 - 1624
Main Authors Curns, Aaron T., Steiner, Claudia A., Barrett, Marguerite, Hunter, Katherine, Wilson, Emily, Parashar, Umesh D.
Format Journal Article
LanguageEnglish
Published United States The University of Chicago Press 01.06.2010
University of Chicago Press
Subjects
Online AccessGet full text
ISSN0022-1899
1537-6613
1537-6613
DOI10.1086/652403

Cover

Loading…
Abstract Background. In 2006, RotaTeq (RV5) was recommended for routine vaccination of United States (US) infants. We compared hospitalization rates for acute gastroenteritis among US children aged <5 years during pre-RV5 rotavirus seasons from 2000 through 2006 with those during the post-RV5 2007 and 2008 seasons. Methods. Using 100% hospital discharge data from 18 states, accounting for 49% of the US population, we calculated acute gastroenteritis hospitalization rates for children aged <5 years by rotavirus season, 8 age groups (0–2, 3–5, 6–11, 12–17, 18–23, 24–35, 36–47, and 48–59 months), and state. Results. Compared with the median rate for the 2000–2006 rotavirus seasons (101.1 hospitalizations per 10,000 children), the rates for 2007 and 2008 (85.5 and 55.5 hospitalizations per 10,000 children) were 16% and 45% lower, respectively. Children aged 0–2 months had a 28% reduction, those aged 6–23 months had a reduction of 50%, and children aged 3–5 months and 24–59 months had reductions ranging between 42% and 45% during the 2008 rotavirus season, compared with the median rate for 2000–2006 rotavirus seasons. Conclusions. The introduction of the RV5 vaccine was associated with a dramatic reduction in hospitalizations for acute gastroenteritis among US children during the 2008 rotavirus season.
AbstractList In 2006, RotaTeq (RV5) was recommended for routine vaccination of United States (US) infants. We compared hospitalization rates for acute gastroenteritis among US children aged <5 years during pre-RV5 rotavirus seasons from 2000 through 2006 with those during the post-RV5 2007 and 2008 seasons. Using 100% hospital discharge data from 18 states, accounting for 49% of the US population, we calculated acute gastroenteritis hospitalization rates for children aged <5 years by rotavirus season, 8 age groups (0-2, 3-5, 6-11, 12-17, 18-23, 24-35, 36-47, and 48-59 months), and state. Compared with the median rate for the 2000-2006 rotavirus seasons (101.1 hospitalizations per 10,000 children), the rates for 2007 and 2008 (85.5 and 55.5 hospitalizations per 10,000 children) were 16% and 45% lower, respectively. Children aged 0-2 months had a 28% reduction, those aged 6-23 months had a reduction of 50%, and children aged 3-5 months and 24-59 months had reductions ranging between 42% and 45% during the 2008 rotavirus season, compared with the median rate for 2000-2006 rotavirus seasons. The introduction of the RV5 vaccine was associated with a dramatic reduction in hospitalizations for acute gastroenteritis among US children during the 2008 rotavirus season.
Background. In 2006, RotaTeq (RV5) was recommended for routine vaccination of United States (US) infants. We compared hospitalization rates for acute gastroenteritis among US children aged <5 years during pre-RV5 rotavirus seasons from 2000 through 2006 with those during the post-RV5 2007 and 2008 seasons. Methods. Using 100% hospital discharge data from 18 states, accounting for 49% of the US population, we calculated acute gastroenteritis hospitalization rates for children aged <5 years by rotavirus season, 8 age groups (0–2, 3–5, 6–11, 12–17, 18–23, 24–35, 36–47, and 48–59 months), and state. Results. Compared with the median rate for the 2000–2006 rotavirus seasons (101.1 hospitalizations per 10,000 children), the rates for 2007 and 2008 (85.5 and 55.5 hospitalizations per 10,000 children) were 16% and 45% lower, respectively. Children aged 0–2 months had a 28% reduction, those aged 6–23 months had a reduction of 50%, and children aged 3–5 months and 24–59 months had reductions ranging between 42% and 45% during the 2008 rotavirus season, compared with the median rate for 2000–2006 rotavirus seasons. Conclusions. The introduction of the RV5 vaccine was associated with a dramatic reduction in hospitalizations for acute gastroenteritis among US children during the 2008 rotavirus season.
Background. In 2006, RotaTeq (RV5) was recommended for routine vaccination of United States (US) infants. We compared hospitalization rates for acute gastroenteritis among US children aged <5 years during pre-RV5 rotavirus seasons from 2000 through 2006 with those during the post-RV5 2007 and 2008 seasons. Methods. Using 100% hospital discharge data from 18 states, accounting for 49% of the US population, we calculated acute gastroenteritis hospitalization rates for children aged <5 years by rotavirus season, 8 age groups (0-2, 3-5, 6-11, 12-17, 18-23, 24-35, 36-47, and 48-59 months), and state. Results. Compared with the median rate for the 2000-2006 rotavirus seasons (101.1 hospitalizations per 10,000 children), the rates for 2007 and 2008 (85.5 and 55.5 hospitalizations per 10,000 children) were 16% and 45% lower, respectively. Children aged 0-2 months had a 28% reduction, those aged 6-23 months had a reduction of 50%, and children aged 3-5 months and 24-59 months had reductions ranging between 42% and 45% during the 2008 rotavirus season, compared with the median rate for 2000-2006 rotavirus seasons. Conclusions. The introduction of the RV5 vaccine was associated with a dramatic reduction in hospitalizations for acute gastroenteritis among US children during the 2008 rotavirus season.
In 2006, RotaTeq (RV5) was recommended for routine vaccination of United States (US) infants. We compared hospitalization rates for acute gastroenteritis among US children aged <5 years during pre-RV5 rotavirus seasons from 2000 through 2006 with those during the post-RV5 2007 and 2008 seasons.BACKGROUNDIn 2006, RotaTeq (RV5) was recommended for routine vaccination of United States (US) infants. We compared hospitalization rates for acute gastroenteritis among US children aged <5 years during pre-RV5 rotavirus seasons from 2000 through 2006 with those during the post-RV5 2007 and 2008 seasons.Using 100% hospital discharge data from 18 states, accounting for 49% of the US population, we calculated acute gastroenteritis hospitalization rates for children aged <5 years by rotavirus season, 8 age groups (0-2, 3-5, 6-11, 12-17, 18-23, 24-35, 36-47, and 48-59 months), and state.METHODSUsing 100% hospital discharge data from 18 states, accounting for 49% of the US population, we calculated acute gastroenteritis hospitalization rates for children aged <5 years by rotavirus season, 8 age groups (0-2, 3-5, 6-11, 12-17, 18-23, 24-35, 36-47, and 48-59 months), and state.Compared with the median rate for the 2000-2006 rotavirus seasons (101.1 hospitalizations per 10,000 children), the rates for 2007 and 2008 (85.5 and 55.5 hospitalizations per 10,000 children) were 16% and 45% lower, respectively. Children aged 0-2 months had a 28% reduction, those aged 6-23 months had a reduction of 50%, and children aged 3-5 months and 24-59 months had reductions ranging between 42% and 45% during the 2008 rotavirus season, compared with the median rate for 2000-2006 rotavirus seasons.RESULTSCompared with the median rate for the 2000-2006 rotavirus seasons (101.1 hospitalizations per 10,000 children), the rates for 2007 and 2008 (85.5 and 55.5 hospitalizations per 10,000 children) were 16% and 45% lower, respectively. Children aged 0-2 months had a 28% reduction, those aged 6-23 months had a reduction of 50%, and children aged 3-5 months and 24-59 months had reductions ranging between 42% and 45% during the 2008 rotavirus season, compared with the median rate for 2000-2006 rotavirus seasons.The introduction of the RV5 vaccine was associated with a dramatic reduction in hospitalizations for acute gastroenteritis among US children during the 2008 rotavirus season.CONCLUSIONSThe introduction of the RV5 vaccine was associated with a dramatic reduction in hospitalizations for acute gastroenteritis among US children during the 2008 rotavirus season.
Author Hunter, Katherine
Curns, Aaron T.
Steiner, Claudia A.
Wilson, Emily
Parashar, Umesh D.
Barrett, Marguerite
Author_xml – sequence: 1
  givenname: Aaron T.
  surname: Curns
  fullname: Curns, Aaron T.
  email: agc8@cdc.gov
  organization: National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia
– sequence: 2
  givenname: Claudia A.
  surname: Steiner
  fullname: Steiner, Claudia A.
  organization: Healthcare Cost and Utilization Project, Center for Delivery, Organization and Markets, Agency for Healthcare Research and Quality, Rockville, Maryland
– sequence: 3
  givenname: Marguerite
  surname: Barrett
  fullname: Barrett, Marguerite
  organization: M.L. Barrett, Del Mar, Santa Barbara, California
– sequence: 4
  givenname: Katherine
  surname: Hunter
  fullname: Hunter, Katherine
  organization: Thomson Reuters, Santa Barbara, California
– sequence: 5
  givenname: Emily
  surname: Wilson
  fullname: Wilson, Emily
  organization: Thomson Reuters, Santa Barbara, California
– sequence: 6
  givenname: Umesh D.
  surname: Parashar
  fullname: Parashar, Umesh D.
  organization: National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia
BackLink https://www.ncbi.nlm.nih.gov/pubmed/20402596$$D View this record in MEDLINE/PubMed
BookMark eNp10c1u1DAQB3ALFdFtgTcAmQtcCPgjtjfcll3oVqpAbWmpuFgTx2ldsvFiO4jyPDwoXqVbJBAX-zC_-Xs03kM7ve8tQo8peUXJVL6WgpWE30MTKrgqpKR8B00IYayg06raRXsxXhNCSi7VA7TLSEmYqOQE_TqxzWCS8z12PZ6ZIVl8ADEFb_tkg0su4qWPa5egcz9hAyOGle8v8dkpnl-5rgk2N7YZ48M-923jfItPfILvLgwRn4Mxrrdv8KyH7ibm0Fze5uKFi-YKwqXFC0iA2-BXmE43D5wmSDY-RPdb6KJ9dHvvo7P37z7Nl8XRx4PD-eyoMKVkqVCmYYpKJRSjytRCqLKqRA2tbKkASoysIR-lKJnNLsuWGrCE1i1VdUP5Pnox5q6D_zbYmPQqT2a7Dnrrh6gV5xXnlMosn97KoV7ZRq-DW0G40dvFZvB8BCb4GINt7wglevNjevyxDF_-BU3eyWaDKYDr_uXPRu6H9f8jn4zmOiYf_sympozxkuV6MdZdTPbHXR3CVy0VV0IvL77o4-MPby8W55_1gv8GQum6Mg
CitedBy_id crossref_primary_10_2222_jsv_60_33
crossref_primary_10_1542_pir_33_10_439
crossref_primary_10_1093_jpids_piw020
crossref_primary_10_1016_j_vaccine_2011_07_117
crossref_primary_10_1093_cid_ciaa150
crossref_primary_10_1097_INF_0000000000000095
crossref_primary_10_1097_INF_0b013e3181fefb32
crossref_primary_10_1093_cid_ciy580
crossref_primary_10_1002_jmv_25075
crossref_primary_10_1016_j_vaccine_2016_11_056
crossref_primary_10_1016_j_vaccine_2017_05_064
crossref_primary_10_2165_11537200_000000000_00000
crossref_primary_10_1016_j_cll_2015_02_012
crossref_primary_10_1093_cid_civ1182
crossref_primary_10_1097_INF_0b013e3181fefa05
crossref_primary_10_1016_j_jcv_2012_10_016
crossref_primary_10_1016_j_vaccine_2013_08_041
crossref_primary_10_1093_infdis_jir477
crossref_primary_10_1093_infdis_jiu503
crossref_primary_10_1002_jmv_23971
crossref_primary_10_1007_s00580_011_1270_z
crossref_primary_10_1097_INF_0b013e31822a8527
crossref_primary_10_1590_0102_311X00124713
crossref_primary_10_4161_hv_24846
crossref_primary_10_1016_j_vaccine_2016_08_047
crossref_primary_10_4161_hv_21577
crossref_primary_10_1155_2013_612403
crossref_primary_10_1590_0102_311X00080515
crossref_primary_10_1097_INF_0000000000001077
crossref_primary_10_3389_fpubh_2015_00269
crossref_primary_10_1016_j_vaccine_2011_07_105
crossref_primary_10_1016_j_vaccine_2016_07_001
crossref_primary_10_3389_fmicb_2020_01526
crossref_primary_10_1186_1471_2431_12_74
crossref_primary_10_1016_j_coviro_2012_05_002
crossref_primary_10_1093_infdis_jir492
crossref_primary_10_1007_s12098_014_1419_2
crossref_primary_10_1016_j_cmi_2016_03_007
crossref_primary_10_1093_jac_dkac339
crossref_primary_10_1097_INF_0b013e3181fefd78
crossref_primary_10_1038_pr_2016_95
crossref_primary_10_1093_jpids_pis058
crossref_primary_10_1097_INF_0000000000000702
crossref_primary_10_1016_j_vaccine_2016_04_014
crossref_primary_10_5144_0256_4947_2013_241
crossref_primary_10_1097_MOP_0b013e32834ee594
crossref_primary_10_1542_peds_2013_3849
crossref_primary_10_1371_journal_pone_0154340
crossref_primary_10_1586_14760584_2014_877846
crossref_primary_10_1186_1824_7288_40_14
crossref_primary_10_1038_s41598_018_19469_w
crossref_primary_10_1056_NEJMoa1311738
crossref_primary_10_1016_j_meegid_2013_05_008
crossref_primary_10_1590_1982_0194201500041
crossref_primary_10_1016_j_virusres_2011_11_021
crossref_primary_10_1016_j_vaccine_2022_04_104
crossref_primary_10_1097_MCG_0000000000000907
crossref_primary_10_1111_irv_12096
crossref_primary_10_2217_imt_12_7
crossref_primary_10_1016_j_vaccine_2011_07_092
crossref_primary_10_1128_JCM_05590_11
crossref_primary_10_1177_0883073814542944
crossref_primary_10_1016_j_vaccine_2013_08_103
crossref_primary_10_1186_1471_2334_13_112
crossref_primary_10_1016_S1473_3099_11_70253_5
crossref_primary_10_1097_INF_0b013e3182254d19
crossref_primary_10_1111_j_1468_0009_2012_00664_x
crossref_primary_10_1016_j_amepre_2012_10_001
crossref_primary_10_1016_j_vaccine_2011_05_017
crossref_primary_10_14776_piv_2016_23_3_202
crossref_primary_10_1016_j_meegid_2017_05_009
crossref_primary_10_1542_peds_2010_1830
crossref_primary_10_1093_cid_cit520
crossref_primary_10_1097_INF_0000000000000086
crossref_primary_10_1016_j_vaccine_2010_08_094
crossref_primary_10_1093_jpids_pix004
crossref_primary_10_1542_peds_2010_1393
crossref_primary_10_1111_j_1440_1754_2010_01953_x
crossref_primary_10_1007_s11908_013_0333_5
crossref_primary_10_2478_prolas_2019_0049
crossref_primary_10_1016_j_jcv_2012_03_010
crossref_primary_10_1007_s00431_010_1245_0
crossref_primary_10_1093_cid_cis443
crossref_primary_10_1097_INF_0000000000001143
crossref_primary_10_1016_S0140_6736_10_60896_3
crossref_primary_10_4161_hv_22341
crossref_primary_10_1542_gr_27_5_49
crossref_primary_10_3346_jkms_2015_30_10_1471
crossref_primary_10_1097_MOP_0b013e32834877f1
crossref_primary_10_1590_0037_8682_0311_2014
crossref_primary_10_1155_2014_720585
crossref_primary_10_1186_1471_2458_11_462
crossref_primary_10_1016_j_cmi_2015_01_027
crossref_primary_10_1586_erv_11_184
crossref_primary_10_1016_j_ijid_2010_11_007
crossref_primary_10_1016_j_yapd_2012_04_002
crossref_primary_10_1186_1471_2334_13_54
crossref_primary_10_1007_s11606_018_4531_6
crossref_primary_10_1093_ofid_ofz115
crossref_primary_10_1016_j_vaccine_2012_11_099
crossref_primary_10_1371_journal_pmed_1001024
crossref_primary_10_1016_j_provac_2011_10_008
crossref_primary_10_3390_v7010378
crossref_primary_10_1371_journal_pntd_0003042
crossref_primary_10_1016_j_vaccine_2025_126789
crossref_primary_10_4161_hv_29386
crossref_primary_10_1080_21645515_2021_1972706
crossref_primary_10_1093_jpids_pit060
crossref_primary_10_4161_hv_7_12_18321
crossref_primary_10_1016_j_vaccine_2014_03_029
crossref_primary_10_1093_cid_civ1027
crossref_primary_10_1097_INF_0b013e31828d639c
crossref_primary_10_1111_j_1440_1754_2012_02445_x
crossref_primary_10_1007_s00431_013_1945_3
crossref_primary_10_1016_j_arcped_2011_07_025
crossref_primary_10_1016_S1473_3099_12_70029_4
crossref_primary_10_1093_infdis_jiw186
crossref_primary_10_1016_j_vaccine_2012_01_022
crossref_primary_10_1016_j_meegid_2014_10_013
crossref_primary_10_1016_j_vaccine_2011_10_108
crossref_primary_10_4081_jphr_2013_e9
crossref_primary_10_1097_INF_0b013e318270362c
crossref_primary_10_1128_JVI_05217_11
crossref_primary_10_4161_hv_20178
crossref_primary_10_4161_hv_22877
crossref_primary_10_4161_hv_28857
crossref_primary_10_1586_erv_10_157
crossref_primary_10_1007_s13312_012_0076_7
crossref_primary_10_5812_jjm_11840
crossref_primary_10_1016_j_medmal_2011_03_001
crossref_primary_10_1016_j_vaccine_2012_02_032
crossref_primary_10_1097_INF_0b013e3181fefa1f
crossref_primary_10_1097_INF_0b013e3181fefd90
crossref_primary_10_1016_j_jegh_2012_11_004
crossref_primary_10_1016_j_vaccine_2011_01_104
crossref_primary_10_1093_jpids_pix057
crossref_primary_10_1097_MPG_0b013e318282aa12
crossref_primary_10_1016_j_pedneo_2013_05_008
crossref_primary_10_1016_j_vaccine_2011_12_002
crossref_primary_10_1097_INF_0b013e3181fefc68
crossref_primary_10_1016_j_vaccine_2012_05_084
crossref_primary_10_4161_hv_7_5_14620
crossref_primary_10_4236_ojped_2014_44040
crossref_primary_10_1016_j_vaccine_2011_04_087
crossref_primary_10_1016_j_vaccine_2016_10_025
crossref_primary_10_1542_peds_2011_2537
crossref_primary_10_1016_j_vaccine_2010_11_028
crossref_primary_10_1002_bdr2_1674
crossref_primary_10_3928_19382359_20200416_01
crossref_primary_10_3389_fmicb_2022_951716
crossref_primary_10_1371_journal_pone_0067763
crossref_primary_10_2471_BLT_13_125286
crossref_primary_10_1186_1741_7015_9_84
crossref_primary_10_1542_hpeds_2013_0064
crossref_primary_10_1185_03007995_2011_555757
crossref_primary_10_1586_eri_12_39
crossref_primary_10_1016_j_vaccine_2011_08_110
crossref_primary_10_2222_jsv_67_99
crossref_primary_10_1093_infdis_jis314
crossref_primary_10_4161_hv_24831
crossref_primary_10_1097_INF_0b013e3181fefdc0
ContentType Journal Article
Copyright 2010 Infectious Diseases Society of America
2010 by the Infectious Diseases Society of America 2010
Copyright_xml – notice: 2010 Infectious Diseases Society of America
– notice: 2010 by the Infectious Diseases Society of America 2010
DBID BSCLL
AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
DOI 10.1086/652403
DatabaseName Istex
CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList MEDLINE


MEDLINE - Academic

Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Biology
EISSN 1537-6613
EndPage 1624
ExternalDocumentID 20402596
10_1086_652403
10.1086/652403
27822342
ark_67375_HXZ_QQNBXDVW_D
Genre Research Support, U.S. Gov't, P.H.S
Comparative Study
Journal Article
Research Support, N.I.H., Extramural
GeographicLocations United States
GeographicLocations_xml – name: United States
GroupedDBID ---
-DZ
-~X
..I
.2P
.I3
.XZ
.ZR
08P
0R~
123
1TH
29K
2AX
2WC
36B
4.4
48X
53G
5GY
5RE
5VS
5WD
70D
85S
AABZA
AACGO
AACZT
AAHBH
AAHTB
AAJKP
AAJQQ
AAMVS
AANCE
AAOGV
AAPNW
AAPQZ
AAPXW
AAQQT
AARHZ
AAUAY
AAUQX
AAVAP
AAWTL
ABBHK
ABDFA
ABEJV
ABEUO
ABGNP
ABIXL
ABJNI
ABKDP
ABLJU
ABNHQ
ABNKS
ABOCM
ABPEJ
ABPLY
ABPPZ
ABPQP
ABPTD
ABQLI
ABQNK
ABTLG
ABVGC
ABWST
ABXSQ
ABXVV
ABZBJ
ACGFO
ACGFS
ACGOD
ACHIC
ACPRK
ACUFI
ACUTO
ACYHN
ADBBV
ADEYI
ADGZP
ADHKW
ADHZD
ADIPN
ADNBA
ADOCK
ADQBN
ADQXQ
ADRTK
ADULT
ADVEK
ADYVW
ADZXQ
AEGPL
AEGXH
AEJOX
AEKSI
AEMDU
AEMQT
AENEX
AENZO
AEPUE
AETBJ
AEUPB
AEWNT
AEXZC
AFFNX
AFFZL
AFIYH
AFOFC
AFXAL
AFYAG
AGINJ
AGKEF
AGORE
AGQXC
AGSYK
AGUTN
AHMBA
AHMMS
AHXPO
AIAGR
AIJHB
AJBYB
AJEEA
AJNCP
ALMA_UNASSIGNED_HOLDINGS
ALUQC
ALXQX
APIBT
APWMN
AQVQM
ATGXG
AXUDD
BAWUL
BAYMD
BCRHZ
BEYMZ
BHONS
BR6
BSCLL
BTRTY
BVRKM
C45
CDBKE
CS3
CZ4
D-I
DAKXR
DCCCD
DIK
DILTD
DU5
D~K
EBS
ECGQY
EE~
EJD
EMOBN
ENERS
F5P
F9B
FECEO
FLUFQ
FOEOM
FOTVD
FQBLK
GAUVT
GJXCC
GX1
H13
H5~
HAR
HW0
HZ~
IH2
IOX
IPSME
J21
JAAYA
JBMMH
JENOY
JHFFW
JKQEH
JLS
JLXEF
JPM
JSG
JST
JXSIZ
KAQDR
KBUDW
KOP
KQ8
KSI
KSN
L7B
LSO
LU7
MHKGH
MJL
ML0
N4W
N9A
NGC
NOMLY
NOYVH
NU-
NVLIB
O0~
O9-
OAUYM
OAWHX
OCZFY
ODMLO
OJQWA
OJZSN
OK1
OPAEJ
OVD
OWPYF
P2P
PAFKI
PEELM
PQQKQ
Q1.
Q5Y
QBD
RD5
ROX
ROZ
RUSNO
RW1
RXO
SA0
SJN
TCURE
TEORI
TJX
TR2
W2D
W8F
WH7
X7H
YAYTL
YKOAZ
YXANX
~91
AAYOK
AASNB
ADACV
ADJQC
ADRIX
AFXEN
DOOOF
ESX
JSODD
M49
.55
.GJ
1KJ
3O-
41~
AAFWJ
AAPGJ
AAWDT
AAYXX
ABDPE
ABSMQ
ACFRR
ACPQN
ACUTJ
ACVCV
ACZBC
ADMTO
AEKPW
AFFQV
AFHKK
AFQQW
AFSHK
AGKRT
AGMDO
AHGBF
AI.
AJDVS
APJGH
AQDSO
AQKUS
AVNTJ
BZKNY
CITATION
EIHJH
HQ3
HTVGU
J5H
MBLQV
MVM
NEJ
OBFPC
O~Y
P0-
TMA
VH1
X7M
Y6R
ZE2
ZGI
ZXP
CGR
CUY
CVF
ECM
EIF
NPM
VXZ
YIF
7X8
ID FETCH-LOGICAL-c462t-7cd2716757217cb5574995baf6f15a10c6ba0c64542e716167f1cae01bf17bd13
ISSN 0022-1899
1537-6613
IngestDate Thu Jul 10 23:59:23 EDT 2025
Wed Feb 19 01:52:50 EST 2025
Thu Apr 24 22:57:27 EDT 2025
Tue Jul 01 03:24:18 EDT 2025
Wed Sep 11 04:51:08 EDT 2024
Fri Jun 20 02:31:42 EDT 2025
Tue Aug 05 16:48:53 EDT 2025
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 11
Language English
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c462t-7cd2716757217cb5574995baf6f15a10c6ba0c64542e716167f1cae01bf17bd13
Notes istex:81DCC38C35CC978FEEC60FC962BBD89D41D44167
ark:/67375/HXZ-QQNBXDVW-D
ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
OpenAccessLink https://academic.oup.com/jid/article-pdf/201/11/1617/18059568/201-11-1617.pdf
PMID 20402596
PQID 733933116
PQPubID 23479
PageCount 8
ParticipantIDs proquest_miscellaneous_733933116
pubmed_primary_20402596
crossref_primary_10_1086_652403
crossref_citationtrail_10_1086_652403
oup_primary_10_1086_652403
jstor_primary_27822342
istex_primary_ark_67375_HXZ_QQNBXDVW_D
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2010-06-01
20100601
2010-06-00
2010-Jun-01
PublicationDateYYYYMMDD 2010-06-01
PublicationDate_xml – month: 6
  year: 2010
  text: 20100601
  day: 1
PublicationDecade 2010
PublicationPlace United States
PublicationPlace_xml – name: United States
PublicationTitle The Journal of infectious diseases
PublicationTitleAbbrev The Journal of Infectious Diseases
PublicationTitleAlternate The Journal of Infectious Diseases
PublicationYear 2010
Publisher The University of Chicago Press
University of Chicago Press
Publisher_xml – name: The University of Chicago Press
– name: University of Chicago Press
References 21878426 - J Infect Dis. 2011 Oct 1;204(7):975-7
20402594 - J Infect Dis. 2010 Jun 1;201(11):1607-10
References_xml – reference: 21878426 - J Infect Dis. 2011 Oct 1;204(7):975-7
– reference: 20402594 - J Infect Dis. 2010 Jun 1;201(11):1607-10
SSID ssj0004367
Score 2.4239788
Snippet Background. In 2006, RotaTeq (RV5) was recommended for routine vaccination of United States (US) infants. We compared hospitalization rates for acute...
Background. In 2006, RotaTeq (RV5) was recommended for routine vaccination of United States (US) infants. We compared hospitalization rates for acute...
In 2006, RotaTeq (RV5) was recommended for routine vaccination of United States (US) infants. We compared hospitalization rates for acute gastroenteritis among...
SourceID proquest
pubmed
crossref
oup
jstor
istex
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 1617
SubjectTerms Age groups
Child, Preschool
Children
Gastroenteritis
Gastroenteritis - epidemiology
Gastroenteritis - prevention & control
Health care costs
Hospitalization
Hospitalization - statistics & numerical data
Hospitalization rates
Humans
Infant
Infant, Newborn
Male
Preventive medicine
Rotavirus
Rotavirus Vaccines - immunology
Surveillance
United States - epidemiology
Vaccination
Vaccines, Attenuated - immunology
VIRUSES
Title Reduction in Acute Gastroenteritis Hospitalizations among US Children After Introduction of Rotavirus Vaccine: Analysis of Hospital Discharge Data from 18 US States
URI https://api.istex.fr/ark:/67375/HXZ-QQNBXDVW-D/fulltext.pdf
https://www.jstor.org/stable/27822342
https://www.ncbi.nlm.nih.gov/pubmed/20402596
https://www.proquest.com/docview/733933116
Volume 201
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bb9MwFLbKJhAvCAaDjpsfgJcqqE7ipOUNdqFC29BYCxUvkZ06UDGlKE0m4PfwE_iBnONLEroiLi9RlTjHUc8X-zj-vnMIeSQhymVKpl7fVzMvVIp7AxkJzw_jmLGZkpKjdvjoOBpNwldTPu10frRYS1Upn6bf1upK_sercA78iirZf_BsbRROwG_wLxzBw3D8Kx-_wbyrjq0oUtzy_yCWZbHARJs6W1Hvo60L4uSWtrrQ5LSRcZsy4XOkrDtzEEEWi1Kcz4tq2TsXKe6-a1l0K4WJs4x7PDrfkuoh3dQIVtgAu9BqpWU7_m2UaDZZhaGCQS92p6gO8XehkamULAp4oiaXJJbntOrFM1EBvNufY2veMRbwrfA_aAE3LxsGiVY9tj954G69o2bVo3TsQWBhRka15pwd2v3mrsrpW-xIjeu6tVNIX-9oRRwTFTaTpCMGHL9ODiaHh8l4fzq-RDZ9WJxg3YyX04ZYFAa6bnH9QK2KVsbqLyHQJr7NXxwbdkVmeWG1o6Oe8XVyzbqKPjfYu0E6Kt8il00B069b5MqRpWbcJN9rMNJ5TjUY6QoY6SoYqQYjnZxSB0aqwUjbYKSLjNZgpBaMz6iDIl52dmkNRYpQpAhFygbYgYHiLTI52B_vjjxbAsRLw8gvvTid-bCij3kMS-dUch7DCp1LkUUZ44L100gKOIQ89BW0g5YZS4XqM5mxWM5YsE028kWu7hB4fjADg1E4Q90NJiaMRMayoQqZ7MOg1CWPnVeS1ObHxzItZ4nmaQyixHivSx7W7T6bjDAXWjzRTq0vi-IT8idjnoym75OTk-MX072375K9LtnWXq8b-hivB6HfJTsAg9-apw4dCcwFuMEncgVvahIHwTAIGIu65LZBTWMZJmufD6OdP998l1xtXrp7ZKMsKnUfIu9SPtBA_wkfTuCP
linkProvider Geneva Foundation for Medical Education and Research
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Reduction+in+acute+gastroenteritis+hospitalizations+among+US+children+after+introduction+of+rotavirus+vaccine%3A+analysis+of+hospital+discharge+data+from+18+US+states&rft.jtitle=The+Journal+of+infectious+diseases&rft.au=Curns%2C+Aaron+T&rft.au=Steiner%2C+Claudia+A&rft.au=Barrett%2C+Marguerite&rft.au=Hunter%2C+Katherine&rft.date=2010-06-01&rft.issn=1537-6613&rft.eissn=1537-6613&rft.volume=201&rft.issue=11&rft.spage=1617&rft_id=info:doi/10.1086%2F652403&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0022-1899&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0022-1899&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0022-1899&client=summon